News | May 16, 2011

Occlutech Wins German Supreme Court Ruling Against AGA/St. Jude Medical


May 16, 2011 - The German Supreme Court (BGH) declared a structural heart occluder patent case to be invalid. In the ruling by the BGH, the court does not see any basis for AGA/St. Jude's claim that the Occlutech atrial septal defects and patent foramen ovale (ASD and PFO) occluders violate any patent brought forward in the litigation and declares earlier German ruling to the contrary invalid.

The German Supreme Court ruling is similar in many aspects to the first instance ruling in the UK, which was confirmed by the appeal court in the UK in mid 2010. The UK ruling is final, as the UK supreme court did not allow an appeal requested by AGA. The favorable German ruling is also similar to first instance as well as appeal court decisions in The Hague in The Netherlands, the last one obtained at the end of 2010, as well as a district court ruling in Stockholm, Sweden, obtained in March 2011.

Throughout the litigation, Occlutech's owners and partners have funded work in maintaining and substantially strengthening Occlutech's own patent position. Meanwhile, a full pipeline of new technologies and products has been developed. In 2011 and 2012, Occlutech expects to launch additional occluders for indications such as patent ductus artery (PDA) and ventricular septal defect (VSD) in addition to second generation ASD and PFO occluders. Also, an innovative left atrial appendage (LAA) occluder and a new generation of stent grafts and cardiac valve intervention technologies are being developed.

Occlutech intends to initiate litigation for substantial damages against AGA/St. Jude.


Related Content

News | Structural Heart Occluders

June 20, 2024 — atHeart Medical, a medical device company establishing a new standard of care for atrial septal defects ...

Home June 20, 2024
Home
News | Structural Heart Occluders

July 14, 2023 — In recent years, transcatheter intervention techniques have emerged as a promising alternative for the ...

Home July 14, 2023
Home
News | Structural Heart Occluders

May 5, 2022 – Joe DiMaggio Children’s Hospital recently announced the successful treatment of a patient with atrial ...

Home May 05, 2022
Home
News | Structural Heart Occluders

October 4, 2021 — U.S. Food and Drug Administration (FDA) has cleared the Abbott Amplatzer Talisman PFO Occlusion System ...

Home October 04, 2021
Home
Feature | Structural Heart Occluders | By Dave Fornell, Editor

September 20, 2021 — Abbott announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Portico ...

Home September 20, 2021
Home
News | Structural Heart Occluders

April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational ...

Home April 20, 2021
Home
Videos | Structural Heart Occluders

Interview with Carey Kimmelstiel, M.D., FACP, FACC, director, cardiac catheterization laboratory, director ...

Home March 24, 2020
Home
Technology | Structural Heart Occluders

June 10, 2019 – W. L. Gore & Associates (Gore) announced the U.S. Food and Drug Administration’s (FDA’s) premarket ...

Home June 10, 2019
Home
News | Structural Heart Occluders

March 27. 2019 — A newly released expert consensus statement provides recommendations for the safe and effective ...

Home March 27, 2019
Home
News | Structural Heart Occluders

February 13, 2019 — Le Bonheur Children's Hospital cardiologists in Memphis, Tenn., implanted the Amplatzer Piccolo ...

Home February 13, 2019
Home
Subscribe Now